EDESA BIOTECH, INC. Royalty Expense
EDESA BIOTECH, INC. (EDSA) reported Royalty Expense of $0 for the 12-month period ending 2020-09-30, per its 10-K filed 2020-12-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2020-12-07
- EDESA BIOTECH, INC. royalty expense for the quarter ending 2019-12-31 was $0.00.
- EDESA BIOTECH, INC. royalty expense for the quarter ending 2018-12-31 was $0.00.
- EDESA BIOTECH, INC. royalty expense for fiscal 2020 was $0.00.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 9 month as first filed | Royalty Expense 12 month |
|---|---|---|---|---|---|
| 2020-09-30 | $0.00 10-K · filed 2020-12-07 | ||||
| 2019-12-31 | $0.00 10-Q · filed 2020-02-13 | ||||
| 2019-09-30 | $20.47K 10-K · filed 2020-12-07 | $20.00K 10-KT · filed 2019-12-12 | |||
| 2018-12-31 | $0.00 10-Q · filed 2020-02-13 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-09 | ||||
| 2016-03-31 | $200.00K 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |